Two weeks ago we explained why a $400,000 price tag and a six-week factory queue were the real limit on cancer therapy. On 19 August, Merck and Moderna won the first Phase 3 in the history of personalised cancer vaccines, using a six-week factory queue. Here is what we said, what happened, and why the point got sharper.
